The BioCentury Show
The BioCentury Show
BioCentury
Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms
29 minutes Posted Jan 23, 2026 at 2:00 am.
Introduction
Cell & Gene Therapy
Women’s Health
Japan’s Biotech Ecosystem
Astellas’ China Strategy
Astellas’ Near-Term Strategy
0:00
29:23
Download MP3
Show notes
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move ideas across the boundaries of biology, manufacturing, regulation and commercialization. That theme threaded through his conversation on The BioCentury Show with Executive Editor Selina Koch, surfacing most clearly in his diagnosis of what Japan’s biotech ecosystem lacks — and i...